KRAS and neoplasm: We have recently reported on the use of cell-free DNA (cfDNA) to monitor tumor burden during the treatment of KRAS-mutated adenocarcinoma [5], a mutation known to be associated with improved outcomes under anti-PD-1 therapy because of its high mutational burden and PD-L1-expression rate [6, 7].